IV and Oral Iron Drugs Markets, 2024 – Increase in Strategic Collaborations and Licensing Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “IV
and Oral Iron Drugs Market – Global Outlook and Forecast 2019-2024”
report has been added to ResearchAndMarkets.com’s
offering.

The IV and oral iron drugs market is expected to reach around $7.69
million by 2024, growing at a CAGR of about 11% during 2018-2024.

The IV and oral iron drugs market is expected to be driven by multiple
factors such as expanding the pool of target population with iron
deficiency, the high demand for non-dextran IV iron therapeutics, the
increasing demand for iron drugs among dialysis and non-dialysis
patients, and the commercial availability of branded iron therapeutics.

The growing prevalence of iron deficiency is driving vendors, government
organizations, and healthcare professionals to increase awareness about
iron replacement therapies. This is expected to impact the IV and oral
iron drugs market significantly. Several types of research and clinical
studies have confirmed that early diagnosis and prompt treatment
improves the quality of life and physical condition of IDA patients and
alleviates fatigue and cognitive deficits. Further, the expected
commercialization of branded IV drugs such as Feraccru, Monofer, and
Injectafer in newer markets will contribute to the growth of the global
IV and oral iron drugs market.

Currently, the IV and oral iron drugs market is scaling new heights due
to the increase in strategic collaborations and licensing opportunities.
These strategic partnerships and in-licensing/out-licensing
opportunities will allow key players to gain competitive advantage and
increase geographical reach.

Further, they will also reduce R&D expenses and offer scope for easy
market access among geographies. Originator companies are partnering
with large and medium-sized, regional and local, and biotechnology
companies to increase the penetration of IV and oral iron drugs
worldwide. They are also opting for strategic alliances to receive
additional funds for the continued commercialization of drugs among
geographies.

IV and Oral Iron Drugs Market: Segmentation

This market research report includes a detailed segmentation of the
market by Route of Administration (ROA), application, and geography. The
IV and oral iron drugs market by ROA can be segmented into oral iron
drugs and intravenous (IV) iron drugs. The oral iron drugs segment
captured more than half of the market in 2018. Oral iron drugs are
generally used as the first line of treatment to overcome iron
deficiency among children, adults, especially pregnant women. The IV
iron drugs market is growing at a faster rate due to expected launches
of several branded IV iron drugs in the medicine market.

One of the major factors for the significant growth for IV iron drugs is
the increased uptake of branded IV drugs in the US and European markets.
Hence, the rising global medicine and healthcare expenditure and the
accurate and convenient access to IV iron dosages are expected to drive
IV and oral iron drugs market during the forecast period. The IV and
oral iron drugs market by application is segmented into nephrology,
OBGYN, surgeries, gastroenterology, oncology, and heart failure. In
2018, the nephrology segment accounted for a share of more than half of
the IV and oral iron drugs market.

The availability of approved prescription iron drugs and the increased
demand for IV iron drugs, especially in developed economies for treating
ID/IDA in CKD patients are further driving market growth. Over the past
few years, the IV and oral iron drugs market has witnessed new IV iron
formulations such as iron sucrose. It is replacing high molecular weight
iron dextran, especially in dialysis patients. The OBGYN segment
constituted around one-third share of the IV and oral iron drugs market
in 2018.

Also, the IV and oral iron drugs market for gastroenterology is growing
at a significant rate and is likely to increase at a similar pace during
the forecast period due to the increased need for iron drugs among
patients with GI diseases such as IBD and celiac disease.

Key Vendor Analysis

The IV and oral iron drugs market is characterized by the presence of a
few global and many regional and local players. The vendors are offering
branded oral and IV iron drugs, which are generating significant
revenues, especially Europe and the US. Therefore, the IV and oral iron
drugs market has huge growth potential for branded drugs in these
markets. The demand for branded drugs is low in many developing and
low-income countries due to the availability of low-cost generic drugs,
especially oral iron drugs.

Key Topics Covered:

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.2 Base Year

4.3 Scope of the study

4.4 Market Segments

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at A Glance

7 Introduction

7.1 Iron Deficiency: An Overview

7.1.1 Symptoms of ID

7.1.2 Causes of ID

7.1.3 Treatment

8 Market Dynamics

8.1 Market Growth Enablers

8.1.1 Expanding Population Pool with Iron Deficiency

8.1.2 High Demand for Non-dextran IV Iron Therapeutics

8.1.3 Rising Demand Among Dialysis and Non-dialysis Patients

8.2 Market Growth Restraints

8.2.1 Adverse Events Associated with Oral & IV Iron Drugs

8.2.2 Presence of Alternative Options for Treating ID and IDA

8.2.3 Availability of Low-cost Generic Iron Drugs

8.3 Market Opportunities & Trends

8.3.1 Investigational Iron Drugs and Expected Approvals in Newer Markets

8.3.2 Increase in Strategic Collaborations and Licensing Opportunities

8.3.3 Availability of Branded Iron Therapeutics and Expanded Indication
Approvals

9 Global IV & Oral Iron Drugs Market

9.1 Market Overview

9.2 Market Size & Forecast

9.3 Five Forces Analysis

10 By Route Of Administration

10.1 Market snapshot & Growth Engine

10.2 Market Overview

10.3 Oral Iron Drugs

10.4 IV Iron Drugs

11 By Application

11.1 Market Snapshot & Growth Engine

11.2 Market Overview

11.3 Nephrology

11.4 Obstetrics and Gynecology (OBGYN)

11.5 Surgeries

11.6 Gastroenterology

11.7 Oncology

11.8 Heart failure

12 By Geography

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

Competitive Landscape

Leading Vendors

• Daiichi Sankyo Company
• Vifor Pharma

Other Prominent Vendors

• Akebia Therapeutics
• Business Overview
• Major Product Offerings
• Allergan
• AMAG Pharmaceuticals
• AOP Orphan Pharmaceuticals
• Pharmacosmos
• Sanofi
• Shield Therapeutics

Other Vendors

• AZAD Pharma
• Cirondrugs
• MEDICE
• Pfizer
• Salveo Lifecare
• Sunny Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/dn9q2w

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs